Karyopharm Therapeutics announced plans to begin a global randomized clinical trial for low dose oral selinexor (Xpovio) in hospitalized patients with severe coronavirus disease 2019 (COVID-19).
Currently, selinexor, a selective inhibitor of nuclear export compound which blocks the cellular protein XP01, is approved at higher doses by the FDA as a treatment for patients with relapsed or refractory multiple myeloma.
As of now, selinexor is the only XPO1 inhibitor approved by the FDA for commercial use and has been extensively tested in clinical trials across numerous cancer indications globally since 2012. The proposed clinical trial treating hospitalized patients with COVID-19 would be the first study of an XPO1 inhibitor in patients with severe viral infections.
“While Karyopharm’s clinical development strategy until now has been focused on patients with various types of…
